Global Primary Immunodeficiency Therapeutics Market Size (2024 - 2029)

The Primary Immunodeficiency Therapeutics Market is projected to experience growth driven by factors such as the increasing prevalence of immunodeficiency diseases and advancements in genetic therapy. The market's expansion is influenced by the heightened need for effective therapeutics due to rising innate immune disorders. Additionally, proactive company initiatives in product development are expected to contribute to market growth. However, challenges such as the high cost of therapies and potential side effects may impede the market's progress.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Immune System Drugs Research Immunodeficiencies Research Primary Immunodeficiency Therapeutics Industry Market Size

Market Size of Global Primary Immunodeficiency Therapeutics Industry

primary immunodeficiency therapeutics market
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 6.10 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Global Primary Immunodeficiency Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Primary Immunodeficiency Therapeutics Market Analysis

The Primary Immunodeficiency Therapeutics Market is expected to register a CAGR of 6.1% during the forecast period.

The COVID-19 pandemic and the lockdown restrictions imposed by the government to avoid the spread of coronavirus have impacted the market growth. According to an article published in March 2022, titled 'The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study', the study was conducted in Iran from March 2020 to May 2021, and it has been found that among 90 primary immunodeficiency patients, 5 were having combined immunodeficiency disease and 4 were having primary antibody deficiencies (PADs). Additionally, as per a news published in January 2022, following SARS-CoV-2 infection, the United Kingdom Primary Immunodeficiency Network (UK PIN) compiled the health outcomes of 310 people with primary immunodeficiency diseases (PID) or secondary immunodeficiency diseases (SID) between March 2020 and July 2021 and it has been observed that 218 individuals were having PID and 92 SID. The COVID-19 virus poses a higher risk to people with primary and secondary immunodeficiencies because their immune systems are less capable of providing adequate defense against serious illness. Thus, impacting the market growth.

Certain factors that are propelling the market growth are the rising prevalence of immunodeficiency diseases and technological advancements in genetic therapy.

The increasing number of various immunodeficiency diseases is the key factor driving the market growth. For instance, according to an article published in January 2021, titled 'Primary immunodeficiency diseases treated with immunoglobulin and associated comorbidities', it has been observed that chronic obstructive pulmonary disease-asthma (51.5%) was statistically significantly more common as a comorbid diagnosis in the primary immunodeficiency disease population, followed by rheumatoid disease (14%), deficiency anemia (11.8%), hypothyroidism (21.2%), lymphoma (16.7%), neurologic disorders (9.7%), arrhythmias (19.9%), electrolyte disorders (23.6%), coagulopathies (16.9%), and weight loss (8.4%).

Additionally, according to an article in July 2021, titled 'Rhinitis prevalence and association with atopic dermatitis, as per the meta-analysis the pooled prevalence of rhinitis was 40.5% in patients with atopic dermatitis and 18% in patients without atopic dermatitis, in 2020. In addition, as per the same source, the pooled prevalence of rhinitis and asthma was 14.2% in patients with atopic dermatitis. Thus, the rising innate immune disorders are expected to increase the need for effective immunodeficiency therapeutics which in turn is anticipated to propel the market growth over the forecast period.

Furthermore, the rising company activities in developing products are also expected to increase the market growth over the forecast period. For instance, in October 2020, the European Commission granted orphan drug designation for leniolisib for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA).

However, the high cost of therapies and side effects associated with the treatment are likely to hinder the market growth over the forecast period.

Primary Immunodeficiency Therapeutics Industry Segmentation

As per the scope of the report, primary immunodeficiencies are a group of different disorders in which part of the body's immune system (mainly cells and proteins) is missing or does not function normally. The Primary Immunodeficiency Therapeutics Market is segmented By Disease Type (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, and Others), Product Type (Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Disease Type
Antibody Deficiency
Cellular Immunodeficiency
Innate Immune Disorders
Others
By Product Type
Immunoglobulin Replacement Therapy
Stem Cell/Bone Marrow Transplantation
Antibiotic Therapy
Gene Therapy
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Primary Immunodeficiency Therapeutics Market Size Summary

The primary immunodeficiency therapeutics market is poised for steady growth, driven by the increasing prevalence of immunodeficiency diseases and advancements in genetic therapy. The market is experiencing a resurgence as companies focus on developing innovative treatments, including gene therapy, to address the rising demand for effective therapeutics. The COVID-19 pandemic has highlighted the vulnerabilities of individuals with primary immunodeficiency diseases, further underscoring the need for robust therapeutic solutions. Despite challenges such as high treatment costs and potential side effects, the market is expected to expand, supported by ongoing research and development activities and regulatory approvals for new therapies.

North America is anticipated to maintain a significant share of the market, bolstered by its advanced healthcare infrastructure and substantial healthcare expenditure. The region's focus on technological advancements in genetic and stem cell therapy is expected to drive market growth. The presence of major players in the market, coupled with their strategic initiatives, is likely to enhance the development and availability of therapeutics for primary immunodeficiency diseases. As the market evolves, the gene therapy segment is expected to witness notable growth, fueled by the successful application of gene editing and addition techniques in treating various immunodeficiency conditions.

Explore More

Global Primary Immunodeficiency Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Immunodeficiency diseases

      2. 1.2.2 Technological Advancements in Genetic Therapy

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of the Therapies

      2. 1.3.2 Side Effects Associated with the Treatment

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Disease Type

      1. 2.1.1 Antibody Deficiency

      2. 2.1.2 Cellular Immunodeficiency

      3. 2.1.3 Innate Immune Disorders

      4. 2.1.4 Others

    2. 2.2 By Product Type

      1. 2.2.1 Immunoglobulin Replacement Therapy

      2. 2.2.2 Stem Cell/Bone Marrow Transplantation

      3. 2.2.3 Antibiotic Therapy

      4. 2.2.4 Gene Therapy

      5. 2.2.5 Others

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Primary Immunodeficiency Therapeutics Market Size FAQs

The Global Primary Immunodeficiency Therapeutics Market is projected to register a CAGR of 6.10% during the forecast period (2024-2029)

Baxter international Inc, Takeda Pharmaceutical Company Limited, CSL Ltd, Octapharma AG and Biotest AG are the major companies operating in the Global Primary Immunodeficiency Therapeutics Market.

Primary Immunodeficiency Therapeutics Market Report Snapshots

Primary Immunodeficiency Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)